Dehydrated Alcohol

Manufacturer
Valesco Pharmaceuticals
Effective date
2014-07-18
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
2
Source
legacy-cache
Hydrated at
2026-08-02 01:35:44

Label at a glance#

ProductDehydrated Alcohol
Active ingredientALCOHOL
Label structure12 sections

Indications and uses

Dehydrated Alcohol Injection is indicated for therapeutic neurolysis of nerves or ganglia for the relief of intractable chronic pain in such conditions as inoperable cancer and trigeminal neuralgia (ticdouloureux), in patients for whom neurosurgical procedures are contraindicated. Relief of trigeminal neuralgia usually is only temporary. Other conditions for which injection of alcohol has been reported include glo...

Dosage and administration

The dosage of Dehydrated Alcohol Injection for therapeutic nerve or ganglion block varies from as little as 0.05 to 0.5 mL in trigeminal neuralgia to 0.5 to 1.0 mL per interspace for subarachnoid injections. Doses larger than 1.5 mL are seldom required. All injections should be made slowly and only after all steps have been taken to insure precise placement of the alcohol. A 1.0 mL tuberculin syringe is desirable ...

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

Dehydrated Alcohol Injection, USP consists of not less than 98% by volume of ethanol (ethyl alcohol). Dehydrated alcohol is hypobaric in relation to the cerebrospinal fluid. It is injected proximate to nerve tissues and into spinal subarachnoid spaces to produce degeneration of nerve function (neurolysis) for control of chronic pain.

The product contains no bacteriostat or antimicrobial agent (other than ethanol) and no added buffer.

Dehydrated alcohol is a clear, colorless liquid miscible with water and has the following structural formula:

DE-ALcohol moleculeDE-ALcohol molecule

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Alcohol produces injury to tissue cells by dehydration and precipitation of protoplasm. When alcohol is injected in close proximity to nerve tissues, it produces neuritis and nerve degeneration (neurolysis). Deliberate injury to selected spinal nerves, peripheral nerves, or ganglia by injection of alcohol results in more or less enduring block of sensory, motor and autonomic function.

The injection of alcohol used for therapeutic neurolysis involves amounts too small to produce significant systemic effects of ethanol.

Ninety to 98% of ethyl alcohol that enters the body is completely oxidized.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Dehydrated Alcohol Injection is indicated for therapeutic neurolysis of nerves or ganglia for the relief of intractable chronic pain in such conditions as inoperable cancer and trigeminal neuralgia (ticdouloureux), in patients for whom neurosurgical procedures are contraindicated. Relief of trigeminal neuralgia usually is only temporary. Other conditions for which injection of alcohol has been reported include glossopharyngeal neuralgia, angina pectoris and severe claudication due to peripheral vascular insufficiency. Alcohol concentrations of 40 to 50% (prepared by appropriate dilution of dehydrated alcohol) have been used for epidural or individual motor nerve injections to control certain manifestations of cerebral palsy and spastic paraplegia. Similar concentrations also have been injected for celiac plexus block to relieve pain of inoperable upper abdominal cancer, and have been injected intra-and subcutaneously for relief of intractable pruritus ani.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Subarachnoid injection of dehydrated alcohol is contraindicated in patients receiving anticoagulants because of the danger of bleeding.

WARNINGS

WARNINGS SECTION

Alcohol is a flammable liquid and should be kept cool and away from any heat source. Alcohol injections should be made with care to avoid unwanted tissue necrosis. Proper positioning of the patient is essential to control localization of injections of dehydrated alcohol (which is hypobaric) into the subarachnoid space.

PRECAUTIONS

PRECAUTIONS SECTION

Do not administer unless solution is clear and container is intact. Discard unused portion.

It is sometimes advisable to make a trial injection of procaine or other local anesthetic prior to alcohol injection as a means of confirming accurate placement of the needle, and to decrease pain experienced during the procedure. X-ray visualization for precise placement also may be advisable.

When used for selective sensory block within the subarachnoid space, it is essential to avoid contact of the alcohol with the anterior (motor) roots of the spinal nerve to be treated if motor paralysis is not desired. When peripheral nerves are injected, care should be taken that residual alcohol is not deposited along the needle track or in any other locations where tissue destruction is not wanted. Instances have been reported in which the pain resulting from post-injection neuritis was more severe than that existing before the injection.

Pregnancy

Pregnancy Category C: Animal reproduction studies have not been conducted with dehydrated alcohol. It is also not known whether dehydrated alcohol can cause fetal harm when given to a pregnant woman or can affect reproduction capacity. Dehydrated alcohol should be given to a pregnant woman only if clearly needed.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The most commonly encountered side effects are post-injection neuritis with persistent pain, hyperesthesia and paresthesia. Subarachnoid neurolysis and lumbar sympathetic block may be followed by motor paralysis, bladder or rectal incontinence and impotence. Severe hypotension may follow celiac ganglion injection. Corneal anesthesia, meningitis or cranial nerve palsy may follow injection of the gasserian ganglion.

DRUG ABUSE AND DEPENDENCE

DRUG ABUSE AND DEPENDENCE SECTION

None known with this size and manner of presentation.

OVERDOSAGE

OVERDOSAGE SECTION

Excessive or faulty localization of injections may result in unwanted post-injection neuritis and/or tissue necrosis.

In such cases, efforts should be directed toward dilution of deposited alcohol when feasible, relief of pain with analgesics and surgical intervention if indicated.

Hypotension following celiac ganglion injection may be controlled with appropriate vasopressor agents. See PRECAUTIONS and ADVERSE REACTIONS.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

The dosage of Dehydrated Alcohol Injection for therapeutic nerve or ganglion block varies from as little as 0.05 to 0.5 mL in trigeminal neuralgia to 0.5 to 1.0 mL per interspace for subarachnoid injections. Doses larger than 1.5 mL are seldom required. All injections should be made slowly and only after all steps have been taken to insure precise placement of the alcohol. A 1.0 mL tuberculin syringe is desirable to facilitate accurate measurement of the dose. Separate needles should be used for injection of successive interspaces or other sites. Since Dehydrated Alcohol Injection is hypobaric as compared to spinal fluid, proper positioning of the patient is essential to control localization of injections into the subarachnoid space.

When lesser concentrations of alcohol are used, larger volumes are usually injected. A dose of 2 mL of 45% alcohol has been used for injecting individual motor nerves, or from 1.5 to 4.0 mL for epidural injection in children with spastic cerebral palsy; 50 mL of 50% alcohol has been used for celiac plexus blockade.

The LD50 oral dose in rats is 13.7 g/kg.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. See PRECAUTIONS.

HOW SUPPLIED

HOW SUPPLIED SECTION

Dehydrated Alcohol Injection, USP

NDC 44827-303-01 1 mL Ampule Package of 5

NDC 44827-303-05 5 mL Ampule Package of 5

Store in a cool place away from any heat source.

Valesco Pharmaceuticals LLC

175 South 211th Street

Elkhorn, Nebraska 68022

Rev 04/13

Dehydrated Alcohol Injection 1mL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Dehydrated Alcohol boxDehydrated Alcohol box

Dehydrated Alcohol Injection  5mL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Dehydrated Alcohol box 5 x 5mlDehydrated Alcohol box 5 x 5ml

Product Linked Resources#

Resource, Code type, Value table
ResourceCode typeValueEquivalent identifiersSource image
BarcodeEAN-130754986369759GTIN-13: 0754986369759
EAN-13: 0754986369759
GTIN-12: 754986369759
UPC-A: 754986369759
GTIN storage (14 digits): 00754986369759
Dehydrated Alcohol box .jpg

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
44827-303-012019-11-27C16284748780-19855e2a2-4cb0-60a7-e053-dbdaa90a05bd6361091f-c341-4bc7-a2a5-bd6ea73cc028
44827-303-052019-11-27C16284748780-19855e2a2-4cb0-60a7-e053-dbdaa90a05bd6361091f-c341-4bc7-a2a5-bd6ea73cc028

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
44827-303DEHYDRATED ALCOHOL (DEHYDRATED ALCOHOL INJECTION) SOLUTION [VALESCO PHARMACEUTICALS]2Legacy NDC20140718_6361091f-c341-4bc7-a2a5-bd6ea73cc028.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
44827-303-01ML - Milliliter44827-303f96edfac-f9fd-46a5-8850-54c2f769b76812014-09-03

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
ALCOHOLACTIVE INGREDIENT3K9958V90M2
ALCOHOLACTIVE MOIETY3K9958V90M2

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 3 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
44827-30344827-303-01, 44827-303-05

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 1 matching rows.

Name, UNII, Kind table
NameUNIIKind
ALCOHOL3K9958V90MACTIB

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
4b9417d2-4f1b-7d75-e063-6394a90ab1596361091f-c341-4bc7-a2a5-bd6ea73cc0282026-03-17Warnings, Adverse reactionsExact identifier
spl set id: 6361091f-c341-4bc7-a2a5-bd6ea73cc028

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.